About Deargen
Deargen is a company based in Seoul (South Korea) founded in 2016. Deargen has raised $17 million across 1 funding round from investors including Korean Development Bank, Nvester and The Wells Investment. Deargen offers products and services including Dr. UG, DearTRANS, WX Biomarker Prediction, DearDTI, and MolEQ. Deargen operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Deargen Co., Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17 M (USD)
in 1 rounds
-
Latest Funding Round
$17 M (USD), Series B
Feb 24, 2022
-
Investors
Korean Development Bank
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Deargen
Deargen offers a comprehensive portfolio of products and services, including Dr. UG, DearTRANS, WX Biomarker Prediction, DearDTI, and MolEQ.
AI tool for drug development via deep learning technology.
Service for analyzing genome data in drug research.
Platform for predicting biomarkers in precision medicine.
Tool for selecting molecules in drug optimization.
System for optimizing drug leads using AI.
People of Deargen
Unlock access to complete
Funding Insights of Deargen
Deargen has successfully raised a total of $17M through 1 strategic funding round. The most recent funding activity was a Series B round of $17 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Deargen
Deargen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Korean Development Bank, Nvester and The Wells Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in South Korea are managed.
|
Locked | Locked | Locked | |
|
Financial support is provided to ventures by Hana Ventures.
|
Locked | Locked | Locked | |
|
Delivers comprehensive financial services tailored for the investment industry.
|
Locked | Locked | Locked |
Investor details for Deargen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Deargen
Investment portfolio details for Deargen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Deargen
Detailed financials for Deargen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Deargen Comparisons
Peer comparison for Deargen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Deargen
Deargen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Deargen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Deargen
Complete news archive for Deargen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Deargen
Deargen was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Deargen is headquartered in Seoul, South Korea.
Gilsu Kang is the current CEO of Deargen.
Deargen is a funded company, having raised a total of $17M across 1 funding round to date.
Deargen was founded in 2016 in Seoul, South Korea, within the biotechnology sector. An AI-driven platform is operated to address rare and intractable diseases through genome data analysis, biomarker prediction, molecule selection, and optimization processes. New disease targets are identified via this technology to support the development of small molecule precision medicines. Operations focus on accelerating drug discovery for underserved medical needs.
Deargen's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Deargen offers Dr. UG, DearTRANS, WX Biomarker Prediction, DearDTI, and MolEQ.
Deargen has 5 investors. Key investors include Korean Development Bank, Nvester, The Wells Investment, T S Investment, and Hana Ventures.